Sleep-Disordered Breathing Diagnostics

Sleep-disordered breathing (SDB) — obstructive sleep apnea, central sleep apnea, hypoventilation, and complex sleep apnea — is the most common indication for sleep studies. The diagnosis requires recognition of specific respiratory event patterns, calculation of severity indices, and consideration of clinical context. Home sleep apnea testing (HSAT) has expanded access, but PSG remains essential for certain populations. This page covers the scoring of apneas, hypopneas, and respiratory effort-related arousals; AHI categorization; specific SDB phenotypes; and the integration of PSG and HSAT into clinical practice.

Respiratory Event Definitions

Apnea

  • Drop in airflow ≥90% from baseline.
  • Duration ≥10 seconds.
  • Three types based on respiratory effort:
    • Obstructive: continued effort throughout the event.
    • Central: no effort.
    • Mixed: starts central, becomes obstructive.

Hypopnea

  • Drop in airflow ≥30% from baseline.
  • Duration ≥10 seconds.
  • Associated with desaturation OR arousal.
  • Desaturation criterion varies by payer:
    • Medicare/4% rule: ≥4% desaturation.
    • Commercial insurance/3% rule: ≥3% desaturation or arousal.
  • Both obstructive and central types exist.

Respiratory Effort-Related Arousal (RERA)

  • Crescendo of respiratory effort followed by arousal.
  • Does not meet criteria for apnea or hypopnea.
  • RERA index can identify upper airway resistance syndrome (UARS).

Apnea-Hypopnea Index (AHI)

  • Events per hour of sleep.
  • Severity:
    • Mild: 5–15 events/hr.
    • Moderate: 15–30 events/hr.
    • Severe: >30 events/hr.
  • Note: AHI varies by sleep stage; REM AHI often higher than NREM AHI.
  • Position dependence: supine AHI often higher than lateral.

Specific SDB Disorders

Obstructive Sleep Apnea (OSA)

Pathophysiology

  • Upper airway collapse during sleep.
  • Risk factors: obesity, anatomic narrowing, age, male sex, family history.
  • Persistent effort with absent flow.

Clinical Features

  • Snoring (loud, witnessed apneas).
  • Excessive daytime sleepiness (EDS).
  • Morning headache.
  • Nocturia.
  • Mood, cognitive symptoms.

PSG Findings

  • Obstructive apneas: continued chest/abdominal effort with no flow.
  • Hypopneas with desaturation.
  • Position-dependent (supine worse).
  • REM AHI may be much higher than NREM AHI.

Severity Assessment

  • AHI categorization.
  • Oxygen nadir.
  • Time below 90% saturation.
  • Arousal index.
  • REM AHI vs supine AHI.

Central Sleep Apnea (CSA)

Patterns

  • Cheyne-Stokes breathing: crescendo-decrescendo respiration; common in heart failure.
  • Idiopathic CSA: less common.
  • High-altitude periodic breathing.
  • Opioid-induced CSA.
  • Brainstem stroke-induced.

PSG Findings

  • Apneas with absent respiratory effort.
  • Central hypopneas (reduced effort + flow).
  • Often associated with desaturations.

Hypoventilation Syndromes

Obesity Hypoventilation Syndrome (OHS)

  • Obesity + daytime hypercapnia (pCO₂ >45 mmHg).
  • Combined with OSA in most.
  • PSG: prolonged desaturation during sleep; transcutaneous CO₂ elevation if measured.

Neuromuscular Hypoventilation

  • ALS, muscular dystrophy, post-polio, kyphoscoliosis.
  • PSG: hypoventilation pattern; baseline ABG often abnormal.

Complex Sleep Apnea (Treatment-Emergent CSA)

  • OSA initially, then central apneas emerge with CPAP titration.
  • Often improves over time with continued treatment.
  • May require adaptive servo-ventilation (ASV) in selected cases.

Diagnostic Workflow

Initial Assessment

  • Detailed sleep history.
  • STOP-BANG, Epworth Sleepiness Scale.
  • Examination: BMI, neck circumference, oropharynx (Mallampati class), nasal exam.

Choice of Sleep Study

Home Sleep Apnea Test (HSAT) Preferred When

  • High pre-test probability of OSA.
  • No significant comorbidities (severe pulmonary disease, heart failure, neuromuscular disease).
  • Adult patient.
  • No suspected non-OSA sleep disorders.

PSG Preferred When

  • Comorbid medical disease (heart failure, COPD, neuromuscular).
  • Suspected non-OSA sleep disorder (RBD, parasomnia, narcolepsy).
  • Pediatric patient.
  • Negative HSAT but high clinical suspicion.
  • Treatment titration (CPAP, ASV).

HSAT Limitations

  • No EEG → cannot stage sleep.
  • Underestimates AHI (Total Recording Time vs Total Sleep Time).
  • Cannot reliably detect arousals.
  • Cannot diagnose parasomnias, RBD, narcolepsy.
  • May miss positional or REM-only OSA.
  • Quality varies by device and adherence.

CPAP Titration

Standard PSG-Based Titration

  • Initial CPAP set at 4–6 cm H₂O.
  • Pressure increased in 1 cm H₂O increments every 5 minutes if apneas/hypopneas persist.
  • Target: AHI <5/hr.
  • Monitor for treatment-emergent CSA.

Auto-CPAP

  • Device automatically adjusts pressure based on detected events.
  • Common for initial therapy.
  • Provides flexibility but less ideal for complex titration.

BiPAP (Bi-Level Positive Airway Pressure)

  • Separate inspiratory and expiratory pressure.
  • For obesity hypoventilation, neuromuscular disease, or high pressure requirements.

Adaptive Servo-Ventilation (ASV)

  • For central sleep apnea, complex sleep apnea.
  • Pressure varies dynamically to maintain ventilation pattern.
  • Caution in heart failure with EF <45% (SERVE-HF trial).

Pediatric Sleep-Disordered Breathing

Key Differences

  • Often presenting with snoring, mouth breathing, restless sleep, behavioral problems.
  • Etiology: adenotonsillar hypertrophy (most common), craniofacial syndromes, obesity.
  • Treatment: adenotonsillectomy often curative.
  • PSG: pediatric scoring criteria differ from adults.
  • HSAT: less validated for pediatrics; in-lab PSG preferred.

Severity in Pediatrics

  • Mild AHI ≥1, moderate ≥5, severe ≥10 events/hr (different from adults).
  • Hypopnea criteria slightly different.

Sleep-Disordered Breathing in Specific Conditions

Heart Failure

  • Both OSA and CSA (Cheyne-Stokes) common.
  • Worsens cardiovascular outcomes.
  • Treatment: CPAP for OSA; ASV requires caution (SERVE-HF).

Stroke

  • Pre-stroke: OSA increases stroke risk.
  • Post-stroke: ~50% of stroke patients have SDB; should be screened.
  • Treatment improves recovery and reduces recurrent stroke risk.

Atrial Fibrillation

  • OSA increases AF recurrence after ablation.
  • Treatment improves outcomes.

Neuromuscular Disease

  • Diaphragm weakness → nocturnal hypoventilation.
  • Often preceded by symptoms of orthopnea, morning headache.
  • Treatment: BiPAP or NIV.

Opioid Use

  • Chronic opioid use can cause central sleep apnea.
  • PSG reveals pattern.
  • Opioid reduction may improve.

Treatment Outcomes

CPAP for OSA

  • Reduces AHI, daytime sleepiness, cardiovascular morbidity.
  • Improves quality of life.
  • Adherence challenging (~30% suboptimal).
  • Mask fit, education, and support critical.

Alternatives

  • Mandibular advancement devices: mild-moderate OSA.
  • Upper airway surgery: selected anatomic candidates.
  • Hypoglossal nerve stimulation (Inspire): refractory cases with appropriate anatomy.
  • Positional therapy.
  • Weight loss.

For Central Sleep Apnea

  • Treat underlying cause (heart failure optimization).
  • CPAP or oxygen therapy first-line.
  • ASV with caution in HF.

🔍 Did You Know?

The recognition that obstructive sleep apnea is a major modifiable risk factor for stroke, atrial fibrillation, heart failure, and dementia has transformed how clinical neurologists approach diagnosis and treatment of these conditions. Studies have shown that 50–80% of stroke patients have undiagnosed OSA, and untreated OSA increases recurrent stroke risk by 30–50%. The American Stroke Association now recommends sleep evaluation for stroke patients with symptoms or risk factors. Similarly, cognitive decline and dementia risk are substantially elevated in untreated OSA — likely through chronic intermittent hypoxia and sleep fragmentation effects on hippocampal function. The clinical implications are profound: diagnosing and treating OSA in patients with cardiovascular and cognitive disease is part of comprehensive neurology care, not just sleep medicine. For practicing neurologists, the practical implications: (1) screen stroke patients for OSA (STOP-BANG, Epworth) and refer for sleep evaluation if at risk; (2) consider sleep evaluation in patients with cognitive complaints and OSA risk factors; (3) integrate sleep medicine into AF and heart failure management; (4) understand that CPAP can improve neurologic outcomes, not just daytime sleepiness. The same principle generalizes: sleep disorders interact with many neurologic diseases, and addressing sleep should be part of comprehensive neurologic care. The integration of sleep medicine with stroke, dementia, epilepsy, and movement disorder care is one of the most important advances in contemporary neurology.

Pitfalls and Pearls

  • Apnea: ≥90% airflow drop ≥10 sec; obstructive (with effort), central (no effort), mixed.
  • Hypopnea: ≥30% airflow drop ≥10 sec; payer-specific desaturation criterion.
  • AHI: events per hour; mild 5–15, moderate 15–30, severe >30.
  • HSAT: high pre-test OSA; cannot stage sleep or diagnose other disorders.
  • PSG required: comorbidities, suspected non-OSA disorders, pediatric, treatment titration.
  • REM AHI: often higher than NREM; supine AHI often higher than lateral.
  • Central sleep apnea: heart failure (Cheyne-Stokes), opioid-induced, high-altitude.
  • Obesity hypoventilation: obesity + daytime hypercapnia.
  • Complex sleep apnea: treatment-emergent CSA with CPAP.
  • SERVE-HF: ASV caution in heart failure with EF <45%.
  • Pediatric SDB: lower AHI thresholds; adenotonsillectomy often curative.
  • OSA + stroke: 50–80% of stroke patients; major modifiable risk factor.
  • OSA + AF: increases recurrence after ablation.
  • OSA + cognitive decline: substantial increased risk; treat for prevention.
  • CPAP adherence: ~30% suboptimal; education and support critical.
  • Alternatives to CPAP: mandibular advancement, hypoglossal nerve stim, surgery, weight loss.
  • Treat OSA in neurologic patients: improves outcomes beyond sleep symptoms.

References

  1. Berry RB, Quan SF, Abreu AR, et al. The AASM Manual for the Scoring of Sleep and Associated Events. Version 3. American Academy of Sleep Medicine; 2023.
  2. Epstein LJ, Kristo D, Strollo PJ Jr, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009;5(3):263-276.
  3. Yaggi HK, Concato J, Kernan WN, et al. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med. 2005;353(19):2034-2041.
  4. Cowie MR, Woehrle H, Wegscheider K, et al. Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure (SERVE-HF). N Engl J Med. 2015;373(12):1095-1105.
  5. Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Screening for obstructive sleep apnea in adults: US Preventive Services Task Force recommendation statement. JAMA. 2017;317(4):407-414.
  6. Marcus CL, Brooks LJ, Draper KA, et al. Diagnosis and management of childhood obstructive sleep apnea syndrome. Pediatrics. 2012;130(3):576-584.